NCT03605251View on ClinicalTrials.gov

Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

May 28, 2020

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TAS5315 low dose

Oral administration for 12 or 36 weeks

DRUG

TAS5315 high dose

Oral administration for 12 or 36 weeks

DRUG

Placebos

Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)

Trial Locations (1)

Unknown

Taiho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT03605251 - Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis. | Biotech Hunter | Biotech Hunter